Abstract. Intradialytic hypotension (IDH) is the most common complication of hemodialysis. Symptomatic IDH requires the administration of fluid and often results in the early termination of dialysis, both of which may prevent adequate fluid removal. The optimal fluid for the treatment of IDH remains unknown. A randomized, double-blind, crossover trial was performed in 72 chronic hemodialysis patients to determine whether 5% albumin was more effective than normal saline for the treatment of IDH. The primary outcome measure was the percentage of target ultrafiltration achieved, which was defined as the actual ultrafiltration volume divided by target ultrafiltration volume. Secondary outcome measures included postdialysis BP, time to restore BP, recurrent IDH, and treatment failure (inability to restore BP with 750 ml of study fluid). The percentage of target ultrafiltration achieved was 0.84 Ϯ 0.17 for 5% albumin compared with 0.80 Ϯ 0.16 for saline (P ϭ 0.14). The postdialysis systolic BP (121 Ϯ 19 mmHg versus 117 Ϯ 19 mmHg; P ϭ 0.32), postdialysis diastolic BP (63 Ϯ 9 mmHg versus 61 Ϯ 9 mmHg; P ϭ 0.33), volume of study fluid used to treat IDH (403 Ϯ 170 ml versus 428 Ϯ 191 ml; P ϭ 0.34), time required to restore the BP (7.9 Ϯ 6.6 min versus 9.9 Ϯ 7.5 min; P ϭ 0.09), total nursing time required to manage the hypotensive episode (15.1 Ϯ 7.2 min versus 15.9 Ϯ 7.3 min; P ϭ 0.47), number of treatment failures (22% versus 24%; P ϭ 1.0), and the frequency of recurrent IDH (36% versus 36%) were not significantly different when 5% albumin was used compared with saline. It is concluded that 5% albumin is no more effective than normal saline for the treatment of IDH in chronic hemodialysis patients. Normal saline should be used as the initial fluid for the treatment of IDH.
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Intradialytic hypotension (IDH) is the most common complication of hemodialysis, occurring in 20 to 30% of treatments (1) . IDH is an important clinical problem because associated symptoms, such as nausea and cramps, have a negative impact on health-related quality of life (2) . In addition, IDH often requires the administration of fluids (3) or the early discontinuation of dialysis, both of which may prevent adequate fluid removal (3, 4) . Patients with IDH may ultimately experience the effects of volume overload and chronic underdialysis (5) .
The approach to IDH involves treatment of the acute episode with a volume expander followed by the introduction of new measures to prevent future episodes from occurring. Many interventions to prevent IDH have been studied and include the following: the use of cool dialysate (6) , sodium and ultrafiltration profiling (7, 8) , high dialysate calcium (9) , blood volume control (10) , avoidance of food during dialysis (11) , correction of anemia (12) , and the use of pressor agents such as midodrine (13) .
Hypertonic saline (14) , normal saline (15) , albumin (16, 17) , dextran 70 (14) , hydroxyethylstarch (17), and mannitol (16) all have been used in the acute management of IDH. However, the optimal volume expander for IDH remains unknown because there is a paucity of comparative studies. Only one randomized controlled trial has been performed comparing different volume expanders for IDH (14) . Gong et al. (14) compared 23% saline, 7.5% saline, and dextran 70 using a randomized crossover design in 10 hemodialysis patients. They demonstrated that hypertonic saline could effectively treat IDH and that the addition of an oncotic agent such as dextran may prevent late recurrent IDH. Unfortunately, no comparison was made with normal saline, which is probably the most widely used volume expander for IDH (1, 15) .
Albumin has been used for the treatment of IDH with few data to support this indication (16, 18 -20) . Theoretically, albumin may be preferred over saline because its oncotic properties might permit a greater expansion of the plasma volume. In a randomized trial involving septic patients, 5% albumin increased the extracellular fluid volume by more than double the volume of albumin infused, and approximately half of this expansion occurred in plasma (21) . In contrast, normal saline increased the extracellular fluid volume by the volume of saline infused, and only one quarter occurred in plasma (21) .
The objective of this study was to determine whether volume expansion with a colloid fluid offers any benefit over saline for the treatment of IDH. Accordingly, a double-blind, randomized, controlled trial was performed comparing 5% albumin with normal saline for the acute management of IDH.
Materials and Methods

Study Population
Adult patients who underwent hemodialysis treatments at The Ottawa Hospital for a minimum of 3 mo were eligible to enter the study. All participants had at least three symptomatic episodes of intradialytic hypotension in the 60 d preceding enrollment. Patients with a known sensitivity to albumin were excluded. All participants provided written informed consent. The study was approved by the Ottawa Hospital Research Ethics Board.
Study Design
The study was a randomized three-period crossover design as recommended by Kenward and Jones (22) . Patients were randomized to one of two different treatment sequences (sequence 1 or sequence 2). For sequence 1, the participant received 5% albumin to treat the first episode of hypotension; the second dialysis session with hypotension was treated with normal saline; the third dialysis session with hypotension was also treated with normal saline. For sequence 2, the participant received normal saline to treat the first hypotensive episode followed by 5% albumin for the second and third episodes of hypotension.
The statistician generated the randomization schedule using a random number table. The randomized treatment sequence was assigned to each patient using a unique identification number. For ensuring proper allocation concealment, the statistician was given only the patient's identification number and could not link these numbers to any patient.
The study protocol was activated when the patient developed symptomatic hypotension (Table 1) . Symptomatic hypotension was defined as a fall in the systolic BP below 100 mmHg accompanied by at least one of the following: diaphoresis, nausea, vomiting, cramps, headache, or dizziness. When the predialysis systolic BP was Ͻ100 mmHg, symptomatic hypotension was defined as a fall in the systolic BP of at least 10 mmHg accompanied by one of the symptoms listed above. Asymptomatic hypotension was not treated. Each participant had three episodes of hypotension treated on three separate dialysis sessions. During each episode of symptomatic hypotension, the participant could receive up to 750 ml (3 ϫ 250-ml bottles) of 5% albumin or 750 ml (3 ϫ 250-ml bottles) of normal saline. When recurrent hypotension developed during the same dialysis treatment, the study protocol was not restarted. Additional (unblinded) saline or albumin could be given at the discretion of the attending physician if the BP was not restored with 750 ml of the blinded study fluid. Treatment of recurrent hypotension was left to the discretion of the attending physician. The BP was considered to be restored when the systolic BP was a minimum of 100 mmHg for at least 5 min. When the predialysis systolic BP was Ͻ100 mmHg, the BP was considered to be restored when it returned to baseline for at least 5 min.
All dialysis treatments were performed on Fresenius 2008H machines. Dialysate bicarbonate was 35 mmol/L, and dialysate calcium was 2.5 mmol/L. Seventy-one percent of patients used sodium profiling, and 29% used a fixed dialysate sodium concentration throughout the study period. The dialysate temperature was 36.5°C, 35.5°C, and 35.0°C throughout the study period for 80, 16, and 4% of patients, respectively. Dry weight was determined clinically by the patient's attending nephrologist. The dialysis prescription was not altered during the study period. Kt/V was calculated using the Daugirdas secondgeneration logarithmic equation (23) .
Outcome Measures
The primary outcome measure was percentage of target ultrafiltration achieved and was defined as follows: %Target ultrafiltration achieved ϭ actual ultrafiltration volume/target ultrafiltration volume. Target ultrafiltration volume was the difference between the predialysis weight and the dry weight. Actual ultrafiltration volume was the difference between the predialysis and postdialysis weights.
Secondary outcome measures included postdialysis systolic BP, postdialysis diastolic BP, volume of study fluid used, time to restore BP, total nursing time to treat hypotensive episode (time from onset of symptomatic hypotension until BP restored and the nurse believed that the patient was well enough no longer to need one-to-one attention), treatment failures (inability to restore BP with 750 ml of study fluid), recurrent symptomatic hypotension, and the use of other interventions to treat hypotension (e.g., additional unblinded saline).
Blinding
Commercially prepared 5% albumin (250-ml glass bottles supplied by Bayer Canada) was used in the study. The normal saline was placed in identical 250-ml glass bottles (also supplied by Bayer Canada). All bottles were tightly wrapped with foil so that the contents could not be seen. Plastic intravenous tubing, covered with an opaque sleeve, was supplied with each bottle. In case the study fluid became visible through an opening in the foil or tubing sleeve, a small amount of multivitamin solution was added to the saline so that it was identical in color to the albumin. Bottles were labeled "FLUID A" or "FLUID B". The sequence allocation was placed on the front of the patient's chart for easy reference at the time of a hypotensive episode. Only the pharmacist was aware of the coding of the study solutions. The participants, investigators, research nurses, dialysis nurses, and attending physicians were blinded to the coding of the study solutions. The investigators remained blinded until the analysis of the primary outcome was completed. No attempt was made to judge the success of give a third 250-ml bottle of the same study fluid. 5. If BP not restored 5 min after third bottle of fluid, then discontinue study protocol and record as treatment failure. Attending physician to manage patient at his or her own discretion. 6. If recurrent symptomatic hypotension develops after BP successfully restored, then do NOT give further study fluid. Record event and notify attending physician to manage patient.
blinding by asking patients or study personnel which solution was given.
Statistical Analyses
For the sample size calculation, we tested the null hypothesis that there was no difference between albumin and saline. The alternative hypothesis was that albumin would be superior to saline. For estimating sample size, a chart review of patients with intradialytic hypotension was performed to obtain the mean and SD of the %target ultrafiltration achieved. The mean %target ultrafiltration achieved was 0.83 when intradialytic hypotension occurred and 0.97 when there was no hypotension. The observed within-person SD for the %target ultrafiltration achieved was 0.17. The minimal clinically important difference was obtained from an informal survey of nephrologists with clinical expertise in the treatment of hemodialysis patients (24) . On average, the minimum increase in %target ultrafiltration that would change practice was 0.07. A total sample size of 42 patients would be required assuming a minimally important difference of 0.07, a two-sided ␣ of 0.05, and a ␤ of 0.2 (25) . The calculation was performed using S-Plus software. We randomized Ͼ42 participants because it was assumed that some patients would not complete the study if they received a transplant, died, or had no more episodes of hypotension.
Baseline variables were compared with the 2 test for dichotomous variables and the t test or Wilcoxon signed rank test for continuous variables. Primary and secondary outcome measures were compared with the paired t test, Wilcoxon signed rank test, or McNemar matched pairs test as appropriate. Although there is some controversy about the need to test for carryover and period effect (26), we added these analyses at the request of the editor. A two-tailed P Ͻ 0.05 was considered statistically significant.
For the primary analysis, we included only those who received blinded study fluid on three separate dialysis sessions according to study design. As a secondary analysis, we included patients who did not fully complete the protocol but received blinded study fluid on one or two dialysis sessions. In this secondary analysis, we used standard techniques from meta-analysis to pool treatment effect estimates from patients who completed all three visits with patients who completed only one or two visits. This analysis was performed using inverse variance weighted pooling of mean treatment effect estimates from each group as if they arose from different studies (27) .
The study was sponsored by a grant from the International Therapeutic Fluids Group and Bayer Canada. However, the study was designed, analyzed, and written by the investigators. The investigators collected all of the data and have maintained the database independent of the sponsor.
Results
Seventy-two of 79 eligible patients were randomized: 37 to treatment sequence 1 and 35 to treatment sequence 2 ( Figure  1) . Twenty-seven patients were not assessable because they had no hypotensive episodes (n ϭ 17) or only one or two hypotensive episodes (n ϭ 10) during the study period. There were 45 patients in the final analysis: 23 in sequence 1 and 22 in sequence 2. The randomized groups were well balanced with respect to demographic and clinical characteristics ( Table 2) .
There was no significant difference in the predialysis systolic BP (131 Ϯ 23 mmHg versus 135 Ϯ 20 mmHg; P ϭ 0.40), predialysis diastolic BP (67 Ϯ 15 mmHg versus 67 Ϯ 11 mmHg; P ϭ 0.86), or the target ultrafiltration (3.0 Ϯ 1.5 L versus 3.1 Ϯ 1.3 L; P ϭ 0.46) when 5% albumin was used compared with saline. The actual ultrafiltration was 2.6 Ϯ 1.4 L when 5% albumin was used compared with 2.6 Ϯ 1.2 L for saline (P ϭ 0.58). There was no significant difference in the primary outcome measure when 5% albumin was used to treat hypotension compared with saline ( Table 3 ). The %target ultrafiltration achieved was 0.84 Ϯ 0.17 for 5% albumin compared with 0.80 Ϯ 0.16 for saline (Wilcoxon signed rank test median difference, 0.047; 95% confidence interval, Ϫ0.01 to 0.09; P ϭ 0.14). A secondary analysis was performed by pooling %target ultrafiltration achieved on all patients (n ϭ 55) who received at least one blinded study fluid. This analysis yielded a similar result to the primary analysis (mean difference between 5% albumin and saline, 0.04; 95% confidence interval for the mean difference, Ϫ0.02 to 0.09). There was no significant carryover (P ϭ 0.38) or period effect (P ϭ 0.32).
Secondary outcome measures are reported in Table 3 . The postdialysis systolic BP was 121 Ϯ 19 mmHg when 5% albumin was used and 117 Ϯ 19 mmHg when saline was used (P ϭ 0.32). Similarly, the postdialysis diastolic BP was 63 Ϯ 9 mmHg when 5% albumin was used and 61 Ϯ 9 mmHg when saline was used (P ϭ 0.33). The volume of study fluid (blinded) used to treat the hypotensive episode was 403 Ϯ 170 ml for 5% albumin and 428 Ϯ 191 ml for saline (P ϭ 0.34). The time required to restore the BP (7.9 Ϯ 6.6 min versus 9.9 Ϯ 7.5 min; P ϭ 0.09) and the total nursing time required to treat the hypotensive episode (15.1 Ϯ 7.2 min versus 15.9 Ϯ 7.3 min; P ϭ 0.47) were not significantly different when 5% albumin was used compared with saline. Recurrent symptomatic hypotension occurred with the same frequency in both groups (36% in each group). Other interventions used to treat the hypotensive episode were recorded. The ultrafiltration goal was decreased 11% of the time when 5% albumin was used and 22% when saline was used (P ϭ 0.27). Additional (unblinded) saline was given less often when 5% albumin was used compared with saline (16% versus 36%; P ϭ 0.04). However, the volume of additional saline used was similar whether 5% albumin or saline was used initially (231 Ϯ 136 ml versus 260 Ϯ 214 ml; P ϭ 0.74). No patient received additional (unblinded) albumin. Dialysis was terminated early 40% of the time when 5% albumin was used and 29% when saline was used (P ϭ 0.41).
Discussion
In this randomized, controlled trial of maintenance hemodialysis patients, the use of 5% albumin was not superior to normal saline for the treatment of intradialytic hypotension. There was no significant difference in the primary outcome or 11 of the secondary outcome measures. Only one secondary outcome measure, the need for additional saline, favored the use of 5% albumin for intradialytic hypotension. However, the volume of additional saline given was similar whether 5% albumin or saline was used initially, and the additional saline did not lead to a significant difference in the %target ultrafiltration achieved. The study results exclude a clinically relevant difference in the %target ultrafiltration between the treatments, but a small beneficial effect of 5% albumin cannot be excluded.
From a physiologic perspective, it seems that albumin should be more effective than saline for the treatment of intradialytic hypotension. During ultrafiltration, the plasma refilling rate is dependent on colloid osmotic pressure (28) . Infusion of albumin during a hypotensive episode would be expected to increase colloid osmotic pressure and thus enhance plasma refilling (29) . This assumes that the permeability to albumin is not altered by uremia or chronic hemodialysis. Experimental data support the hypothesis that uremia may induce a state of increased vascular permeability (30, 31) .
Using an in vivo model, Harper et al. (31) demonstrated that serum from uremic patients significantly increased vascular permeability to both water and proteins. It is conceivable that 5% albumin was no better than saline in our study because albumin was not maintained in the vascular space (32) . van der Sande et al. (17, 29) have published two studies evaluating the effect of saline, albumin, and hydroxyethylstarch on the preservation of blood volume and BP during hemodialysis. In their first report, normal saline, 20% albumin, or hydroxyethylstarch was infused into 10 stable hemodialysis patients when the blood volume decreased by Ͼ10% (29) . They showed that the preservation of blood volume was significantly better with hydroxyethylstarch and albumin compared with saline, but there was no significant difference in systolic BP among the three groups (29) . In addition, colloid osmotic pressure increased in all three groups, and there was no significant difference between saline and 20% albumin (29) . In their second report, 3% saline, 20% albumin, or hydroxyethylstarch was infused into nine hypotensive-prone dialysis patients when the systolic BP was Ͻ100 mmHg or when the systolic pressure fell by Ͼ25 mmHg (17). When they compared BP at the time of infusion with the end of dialysis, neither saline nor albumin significantly increased the systolic BP (17). In addition, blood volume continued to fall from time of infusion to end of dialysis for albumin and saline and remained stable for hydroxyethylstarch, although none of the values was statistically significant (17). During this study, only four of the 27 dialysis sessions were complicated by a hypotensive episode (presumably symptomatic hypotension). These results suggest that colloid fluids may be better than saline at preserving blood volume, but this is very different from restoring BP and alleviating symptoms during a severe episode of intradialytic hypotension.
Our results are consistent with a previous study that evaluated a protocol for the treatment of intradialytic hypotension (16). Emili et al. (16) instituted a protocol that used saline, mannitol, and albumin in a stepwise manner for intradialytic hypotension. Although it was not a randomized trial, they showed that most episodes of hypotension could be treated with saline alone. Albumin usage fell from 22 to 6% of dialysis treatments with this protocol (16) . The authors concluded that the protocol was effective and spared the use of albumin.
In our analysis, the patient population consisted of maintenance hemodialysis patients with ESRD. We did not evaluate the role of albumin and saline for the treatment of intradialytic hypotension in the setting of acute renal failure. Jardin et al. (33) showed that albumin infusions given at the start of dialysis resulted in greater ultrafiltration and hemodynamic stability for patients with sepsis-induced acute renal failure. Similarly, Ernest et al. (21) showed that 5% albumin was a better plasma expander than normal saline in a group of septic patients in the intensive care unit. Given the altered physiology of critically ill patients, it is possible that albumin may be better than saline for the management of intradialytic hypotension in patients with acute renal failure.
The strengths of this study included the randomized design with proper allocation concealment. In addition, patients, investigators, and health care providers remained blinded to treatment received until after the primary outcome was analyzed. Only major episodes of hypotension were treated (i.e., associated with symptoms) to make the findings more clinically relevant. The limitations of this study must be noted. Patients in our study were elderly and on dialysis for a substantial period of time. High-risk patients such as these may respond differently to various volume expanders compared with younger, healthier dialysis patients. Because our protocol required three episodes of intradialytic hypotension, only a subset of the total randomized population was included in the final analysis. This may influence the generalizability of our results. It is possible that 5% albumin may be more effective than saline in a stable cohort of dialysis patients with rare episodes of intradialytic hypotension that were not included in this analysis. We used commercially available bottles of isoncotic albumin and identical 250-ml bottles of normal saline to maintain blinding. It is possible that hyperoncotic albumin could have been more effective, but the results of Ernest et al. (21) suggest that isoncotic albumin is a very potent plasma expander. Finally, the primary outcome measure was based on the clinical assessment of dry weight. The difficulties in determining dry weight clinically are well known (34) , and this may have introduced some imprecision into the measurement of the %target ultrafiltration achieved.
In conclusion, this randomized, blinded, clinical trial has shown that 5% albumin is not superior to normal saline for the treatment of intradialytic hypotension in maintenance hemodialysis patients. Albumin is very expensive compared with saline. In a study involving 15 health centers in the United States, the average wholesale acquisition cost for 250 ml of 5% albumin was $50 compared with only $2.50 for the same amount of saline (18) . Given the additional cost of albumin, normal saline should be used as the initial volume expander for intradialytic hypotension. Further research is needed to determine the best volume expander for intradialytic hypotension in the setting of acute renal failure.
